The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is teaming up with Zionexa to urge the U.S. Centers for Medicare and Medicaid Services (CMS) to properly reimburse Cerianna, a radiolabeled F-18 fluoroestradiol radiotracer indicated for use with PET.
The imaging agent is used to detect estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. At the moment, the current rate of reimbursement is $0.752 per millicurie for Medicare patients instead of $608.33 per millicurie.
CMS said any corrections would be retroactive to January 1, but the correction isn't likely to happen until March for April or July implementation, according to the SNMMI.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
